Survival with Olaparib in Metastatic Castration-Resistant Prostate ...
10 дек. 2020 г. ... Results: The median duration of overall survival in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (hazard ratio ...
Effective Testosterone Suppression for Prostate Cancer: Is There a ...
Surgical castration through bilateral orchiectomy is infrequently used today. Intermittent hormonal therapy (IHT) is being investigated as an alternative to ...
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant ...
16 сент. 2021 г. ... Radioligand therapy with 177 Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care ...
Definition of castration - NCI Dictionary of Cancer Terms - NCI
NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine.
Olaparib for Metastatic Castration-Resistant Prostate Cancer
28 мая 2020 г. ... In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who ...
Castration - Wikipedia
Castration causes sterilization (preventing the castrated person or animal from reproducing); it also greatly reduces the production of hormones, such as ...
EZH2 oncogenic activity in castration-resistant prostate cancer cells ...
14 дек. 2012 г. ... Epigenetic regulators represent a promising new class of therapeutic targets for cancer. Enhancer of zeste homolog 2 (EZH2), ...
Genomics of lethal prostate cancer at diagnosis and castration ...
1 апр. 2020 г. ... The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC).
The mutational landscape of lethal castration-resistant prostate cancer
12 июл. 2012 г. ... Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, ...
Effective combinatorial immunotherapy for castration-resistant ...
30 мар. 2017 г. ... Abstract. A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with ...